Pathological Assessment Following Pre-operative Systemic Therapy
There are several specialized pathological evaluation algorithms available to sub-classify response to chemotherapy ranging from simple to complex that provide prognostic survival information. Currently, pathological complete response (pCR) is used as a surrogate marker of overall survival and overall disease-free survival, but pCR does not uniformly predict excellent overall survival. We would like to move away from a binary system of evaluating pathological response to a drug regimen of pCR versus non-pCR so that we identify subtle but potentially significant differences between drug regimens. Following treatment, hormone receptor status and HER2/neu status can change, and repeat hormone receptor studies should be performed on residual disease because changes will impact patient treatment and survival. The traditional prognostic factors of tumor grade and hormone receptor status pre-treatment also contribute to overall survival and disease-free survival in patients with and without a pCR.
KeywordsBreast carcinoma Neoadjuvant chemotherapy Pre-operative systemic therapy Miller-Payne Residual Cancer Burden Hormone receptor Neoadjuvant response index Estrogen receptor HER2/neu AJCC
Papers of particular interest, published recently, have been highlighted as: •Of importance
- 1.NCCN. Clinical practice guidelines in oncology. Breast cancer V.I: National comprehensive cancer network. http://www.nccn.org/professional/physician_gls/f_guidelines.asp (2009).
- 5.• von Minckwitz G, Kaufmann M, Kümmel S, et al. Definition and impact of pathological complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. Results from the German neoadjuvant meta-analysis. [abst 1028]. Presented at ASCO Annual Meeting 2011, Chicago Illinois June 3rd–7th 2011. This reference illustrates that all pCR are not equal for predicting overall survival and disease-free survival and that the hormone receptor status and tumor grade impact the prognostic strength of a pCR.Google Scholar
- 6.Rouzier R, Extra JM, Klijanienko J, et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol. 2002;20(5):1304–10.PubMedCrossRefGoogle Scholar
- 8.Thomas E, Holmes FA, Smith TL, et al. The use of alternate non-cross resistant adjuvant chemotherapy on the bases of pathological response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J Clin Oncol. 2004;22:2294–302.PubMedCrossRefGoogle Scholar
- 12.Von Minckwitz G, Costa SD, Raab G, et al. Dose-dense doxorubicin and docetaxel with or without tamoxifen a spreoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study. J Clin Oncol. 2001;19:3506–15.Google Scholar
- 13.Jackisch C, von Minckwitz G, Eidtmann H, et al. Dose-dense biweekly (8 weeks) versus sequential (24 weeks) neoadjuvant chemotherapy with doxorubicin–cyclophosphamide and docetaxel in operable breast cancer–2nd Interim Analysis of the GABG GEPAR-DUO Trial. Clin Breast Cancer. 2002;3:276–80.PubMedCrossRefGoogle Scholar
- 19.AJCC Cancer staging manual by the American Joint Committee on Cancer (Seventh edition): Edge SB, Byrd DR, Compton CC et al., editors. Springer-Verlag New York NY; 2010. ISBN 978-0-387-88440-0Google Scholar
- 22.Cote R, Giuliano AE, Hawes D, et al. ACOSOG ZOO10: a multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastases in women with clinical T1/T2 N0 M0 breast cancer. J Clin Oncol. 2010;28(Suppl):18–8.Google Scholar
- 23.• Weaver DL, Ashikaga T, Krag D et al. Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med. 2011;364:412–421. This publication is the largest cohort available that reports the pre-treatment significance of isolated tumor cells and micrometastases on overall survival compared with truly node-negative patients.PubMedCrossRefGoogle Scholar
- 24.• Sakakibara M, Nagashima T, Kadowaki M et al. Clinical Significance of Axillary Microresiduals After Neoadjuvant Chemotherapy in Breast Cancer Patients with Cytologically Proven Metastases. Ann Surg Oncol. 2009;16(9):2470–2478. This study, although small, suggests that survival in the setting of isolated tumor cells in lymph nodes post-treatment may cluster with truly node-negative patients rather than with micrometastases that are equivalent to macrometastases pre-treatment.PubMedCrossRefGoogle Scholar
- 25.• Rodenhuis S, Mandjes IAM, Wesseling J, et al. A simple system for grading the response of breast cancer to neoadjuvant chemotherapy. Annals of Oncology 2010 21: 481–487. This article describes a method of estimating response to chemotherapy using standard pathological AJCC classification and data typically available in the patient’s medical record.Google Scholar